ASH Annual Meeting and Exposition
ASH Annual Meeting and Exposition
December 31, 2016
3 min watch
Save

VIDEO: Ibrutinib effective for certain patients with follicular lymphoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN DIEGO — Ajay K. Gopal, MD, director of clinical research at Seattle Cancer Care Alliance, spoke with HemOnc Today at the ASH Annual Meeting and Exposition about the results of the open-label, multicenter, phase 2 DAWN study.

The study showed single-agent ibrutinib (Imbruvica, Janssen) may induce durable responses in patients with chemoimmunotherapy-refractory follicular lymphoma.

Researchers reported median PFS of 4.6 months, 2-year OS of 63% and a median 19.4-month duration of response. The overall response rate was 20.9%.

“If you respond to ibrutinib, your response can be quite long, and we know ibrutinib is relatively well tolerated,” Gopal said. “But I have to admit that the overall response rate was lower than we’d hoped. So, it’s going to be incumbent on us to try to sort out which patients would respond, and if this is a therapy we would consider offering to them if it were FDA approved.” – by Kristie L. Kahl

Reference:

Gopal AK, et al. Abstract 1217. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.

Disclosure: Gopal reports consultant roles with Gilead, Janssen, Seattle Genetics and Spectrum; research funding from Bristol-Myers Squibb, Gilead, Janssen, Merck, Pfizer, Seattle Genetics, Spectrum, Takeda and Teva; and honoraria from Seattle Genetics.